Leadiant Biosciences, Inc. is a pharmaceutical company focused on the research and development of therapies to help improve the lives of people around the world who are affected by rare diseases.

We are driven to provide excellence and innovation because we understand that patients, many of whom have no other treatment options, depend on us for their well-being. This is why rare diseases are an integral part of our research activity and heritage in orphan drug development. In 1984, we became only the fourth company in the world to receive an Orphan Drug Designation in the United States, and since then, we have obtained seven more.

We continue to honor this legacy with our commitment to patients by advancing a diverse pipeline. Our innovative research programs and development of novel product candidates are led by our scientists in partnership with a wide range of physicians, researchers and leading academic and biotechnology organizations around the world.

 This product information is intended for U.S. residents only. The above chart reflects investigational drugs in various stages of clinical development for potential introduction into various markets. Safety and efficacy of the products has not yet been established for the proposed therapeutic areas.

Research Pipeline

Product Candidate Proposed Indication Stage of Development
chenodiol Treatment of cerebrotendinous xanthomatosis (CTX) Phase III
elapegademase Treatment of adenosine deaminase severe combined immunodeficiency (ADA – SCID) sBLA filed
STP-206 Prevention of necrotizing enterocolitis (NEC) Phase I/II